Pharmacy Benefit Managers (PBMs) have become one of the most influential stakeholders in the global pharmaceutical value chain. They determine which medicines receive insurance coverage, negotiate rebates with drug manufacturers, and manage pharmacy networks for insurers and employers. For pharmaceutical companies, access to PBM formularies often determines whether a product reaches millions of patients.

The scale of PBM influence is substantial. PBMs manage prescription drug benefits for more than 275 million Americans and process billions of prescription claims each year.
The industry is highly concentrated: three companies—CVS Caremark, Express Scripts, and OptumRx—control roughly 80% of the U.S. PBM market.

This concentration means that successful pharmaceutical commercialization often depends on effective engagement with a small number of powerful intermediaries. Yet working with PBMs requires a sophisticated understanding of pricing, rebates, regulatory rules, and payer strategy.

This article explains how pharmaceutical companies can collaborate with PBMs effectively, using evidence-based insights, regulatory context, and best practices from industry experts.

Understanding the Role of Pharmacy Benefit Managers

PBMs act as intermediaries between pharmaceutical manufacturers, insurers, employers, pharmacies, and patients. Their primary mission involves managing prescription drug benefits and controlling costs for health plans.

Core Functions of PBMs

PBMs perform several critical functions in the drug supply chain:

• Negotiating drug prices with pharmaceutical manufacturers
• Designing drug formularies that determine insurance coverage
• Processing prescription claims between pharmacies and insurers
• Managing pharmacy networks and mail-order services
• Administering prior authorization and utilization management programs

In essence, PBMs determine which medications receive preferred insurance coverage and at what cost to patients.

A 2023 analysis of prescription claims showed PBMs processed approximately 6.6 billion prescriptions annually in the United States.

Their influence extends across nearly the entire insured population. PBMs currently manage 85% of prescription drug benefits nationwide, making them a central gatekeeper for pharmaceutical market access.

The Economic Power of PBMs

Understanding PBM economics helps pharmaceutical companies negotiate more effectively.

Market Concentration

The PBM sector operates as an oligopoly.

• CVS Caremark: ~33% market share
• Express Scripts: ~24%
• OptumRx: ~22%

Together, these three organizations control the majority of prescription processing and formulary decisions in the United States.

Additional PBMs such as Prime Therapeutics and MedImpact hold smaller shares.

This concentration means that a limited number of negotiations can determine national access to a medication.

Why PBM Relationships Matter for Drug Manufacturers

For pharmaceutical companies, PBMs represent the gateway to reimbursement.

Without formulary inclusion, even highly effective drugs may struggle to achieve commercial success.

Key Reasons PBM Collaboration Matters

• Determines insurance coverage for medications
• Influences patient out-of-pocket costs
• Drives prescribing behavior among physicians
• Shapes market share in competitive therapeutic classes

PBMs use tiered formularies to steer utilization toward preferred products. Drugs with better negotiated rebates often receive favorable placement.

Research indicates that highly rebated drugs are 50% more likely to receive preferred formulary placement compared with lower-rebate alternatives.

For pharmaceutical companies, this means pricing strategy and rebate negotiations strongly affect patient access.

The PBM Formulary System

The formulary represents the most powerful tool PBMs use to manage drug utilization.

What Is a Formulary?

A formulary is a list of medications covered by a health plan. PBMs categorize drugs into tiers that determine reimbursement levels.

Typical Formulary Structure

Placement within these tiers significantly affects prescribing rates.

Physicians often select drugs with lower patient copays, which increases the importance of PBM negotiations.

Strategic Steps to Work Effectively with PBMs

Pharmaceutical companies must approach PBM engagement strategically.

1. Develop a Comprehensive Value Proposition

PBMs focus heavily on economic outcomes.

Drug manufacturers must present a strong clinical and economic value argument.

Essential Elements

• Comparative clinical trial data
• Pharmacoeconomic analyses
• Real-world evidence on patient outcomes
• Cost-effectiveness studies

Health economic modeling can demonstrate how a therapy reduces overall healthcare costs, which resonates strongly with PBMs.

2. Understand PBM Decision Drivers

PBMs evaluate drugs using several criteria:

• Clinical effectiveness
• Cost relative to alternatives
• Rebate potential
• Patient adherence benefits
• Impact on overall healthcare spending

Pharmaceutical companies must tailor their messaging around these priorities.

For example, therapies that reduce hospitalizations may appeal to payers because they lower total healthcare costs.

3. Build Long-Term Contracting Strategies

PBM contracts often include complex rebate structures.

These agreements typically involve:

• Volume-based rebates
• Market share commitments
• Performance-based contracts
• Price protection clauses

Rebates paid by pharmaceutical companies to PBMs have increased dramatically in recent years. Between 2014 and 2021, manufacturer rebates grew from $39.7 billion to $143 billion.

These rebates represent a major component of PBM revenue.

4. Align Market Access Teams with Commercial Strategy

Pharmaceutical companies typically manage PBM relationships through specialized market access teams.

These teams coordinate:

• Pricing strategy
• Payer negotiations
• formulary placement initiatives
• health economics research

Alignment between market access and commercial teams ensures consistent messaging across stakeholders.

Negotiating with PBMs: Best Practices

Negotiations with PBMs require data-driven preparation and careful strategy.

Preparation Checklist

Before entering negotiations, pharmaceutical companies should analyze:

• Competitive drug landscape
• PBM formulary requirements
• Therapeutic alternatives
• Prescribing trends
• Price elasticity within the class

Understanding competitor rebate levels can also influence strategy.

Key Negotiation Levers

Pharmaceutical companies can influence PBM decisions through several mechanisms.

Rebates

Manufacturers offer rebates tied to utilization volume.

Outcomes-Based Contracts

Some agreements link reimbursement to clinical outcomes.

Exclusive Formulary Placement

PBMs may agree to exclusive placement if manufacturers provide substantial rebates.

Regulatory Environment Affecting PBMs

PBM operations face increasing regulatory scrutiny.

Governments and policymakers continue to examine their role in rising drug prices.

Federal Oversight

U.S. regulators such as the Federal Trade Commission have investigated PBM practices related to drug pricing and market competition.

Recent legal actions have targeted PBM rebate structures and formulary decisions, particularly in the insulin market.

State-Level Regulations

Many states have enacted laws governing PBM behavior.

Examples include:

• Transparency requirements for drug pricing
• Restrictions on pharmacy reimbursement practices
• Prohibitions on PBM “gag clauses”

Currently, more than 38 U.S. states have passed legislation limiting gag clauses that prevented pharmacists from informing patients about cheaper alternatives.

These reforms aim to improve transparency in the pharmaceutical supply chain.

Emerging Policy Debates Around PBMs

PBMs remain one of the most debated institutions in healthcare economics.

Critics argue that rebate structures may encourage higher list prices for drugs. Policymakers from both political parties have proposed reforms targeting PBM transparency and competition.

Recent legislative discussions in the United States have focused on restructuring incentives in the drug supply chain to reduce patient costs.

These debates will likely shape future pharmaceutical pricing strategies.

The Role of Data and Analytics in PBM Engagement

Data plays a crucial role in PBM negotiations.

Pharmaceutical companies increasingly use advanced analytics to demonstrate value to payers.

Key Data Sources

• Real-world evidence from claims databases
• Health economic outcomes research
• Patient adherence data
• Population health models

These insights help demonstrate clinical and economic value beyond traditional trial data.

Specialty Drugs and PBM Strategy

Specialty pharmaceuticals represent one of the fastest-growing segments of healthcare spending.

PBMs increasingly focus on specialty drug management through:

• prior authorization programs
• specialty pharmacy networks
• utilization review processes

Specialty pharmacy services accounted for the largest share of PBM services in 2024.

Manufacturers developing biologics or gene therapies must carefully design market access strategies aligned with PBM expectations.

Collaboration Beyond Pricing

Successful PBM relationships extend beyond pricing negotiations.

Pharmaceutical companies increasingly collaborate with PBMs in areas such as:

• patient adherence programs
• digital health tools
• outcomes monitoring initiatives

These collaborations can improve medication adherence and strengthen payer partnerships.

Ethical and Transparency Considerations

PBM relationships also raise ethical questions around pricing transparency and access.

Critics argue that complex rebate structures obscure true drug prices.

Some healthcare experts advocate shifting toward pass-through pricing models, where negotiated discounts go directly to patients.

Recent industry initiatives aim to increase transparency in PBM contracting.

Future Trends in PBM–Manufacturer Relationships

Several emerging trends will shape the future of PBM collaboration.

1. Value-Based Contracting

More PBM agreements will link reimbursement to clinical outcomes.

2. Greater Pricing Transparency

Regulatory pressure may require clearer disclosure of rebates and fees.

3. Digital Health Integration

PBMs may incorporate digital therapeutics and remote monitoring programs.

4. Increased Government Oversight

Policy reforms may restructure the role of PBMs in the drug supply chain.

Practical Recommendations for Pharmaceutical Companies

To succeed in PBM engagement, manufacturers should focus on several strategic priorities.

Build Strong Market Access Capabilities

Companies must invest in teams specializing in payer negotiations and health economics.

Use Real-World Evidence

Demonstrating clinical value through real-world data strengthens negotiation leverage.

Maintain Competitive Pricing Strategies

Pricing decisions should consider rebate expectations and formulary competition.

Develop Long-Term Partnerships

Collaborative relationships with PBMs often produce better outcomes than transactional negotiations.

Conclusion

Pharmacy Benefit Managers sit at the center of the modern pharmaceutical ecosystem. They manage prescription benefits for hundreds of millions of patients, negotiate billions of dollars in drug rebates, and determine formulary access for thousands of medications.

For pharmaceutical companies, success in today’s healthcare market requires mastering PBM engagement.

Effective collaboration demands:

• Strong clinical evidence
• Sophisticated pricing strategies
• Data-driven market access planning
• Deep understanding of regulatory and policy dynamics

As governments increase scrutiny of PBM practices and healthcare systems pursue greater transparency, pharmaceutical companies must adapt their strategies accordingly.

Ultimately, companies that build constructive relationships with PBMs while demonstrating clear therapeutic value will secure better formulary access, improve patient reach, and achieve sustainable commercial success.

References

1. PBM Industry Statistics – ZipDo
   https://zipdo.co/pharmacy-benefit-management-industry-statistics/
2. PBM Market Share and Industry Data – WifiTalents
   https://wifitalents.com/pharmacy-benefit-management-industry-statistics/
3. PBM Market Concentration – JAMA Network
   https://jamanetwork.com/journals/jama/fullarticle/2823618
4. U.S. PBM Market Overview – GlobeNewswire
   https://www.globenewswire.com/news-release/2024/07/24/2918289/0/en/U-S-Pharmacy-Benefit-Management-Market-Size-to-Hit-US-947-90-Billion-By-2032.html
5. Pharmacy Benefit Management Market Analysis – Market.us
   https://media.market.us/pharmacy-benefit-management-market-news/
6. Reuters – FTC insulin investigation involving PBMs
   https://www.reuters.com/business/healthcare-pharmaceuticals/ftc-puts-hold-insulin-lawsuit-against-drug-middlemen-2025-04-02/
7. Washington Post – Congressional debate over PBM reform
   https://www.washingtonpost.com/wp-intelligence/health-brief/2025/11/19/pbm-brawl-is-back/